The abstract is read at the publisher; the summary is JClub's.
Belzutifan plus lenvatinib improved progression-free survival in advanced clear-cell renal-cell carcinoma after anti-PD-(L)1 therapy, with HR 0.74 at final LITESPARK-011 analysis.
- Why it matters: After anti-PD-(L)1 therapy, patients with advanced ccRCC need effective options, and prior results left overall survival unresolved.
- What they did: In this phase 3 randomized open-label trial, adults received 120 mg belzutifan plus 20 mg lenvatinib or 60 mg cabozantinib daily, with PFS and OS as dual primary endpoints.
- The result: At final analysis (data cutoff 2 February 2026), PFS remained favorable (HR 0.74, 95% CI 0.62–0.88), ORR was 53.1% vs 40.2%, and DOR was 22.0 vs 11.9 months, while OS did not reach significance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.